NO328007B1 - Anvendelse av mirtazapin for fremstilling av medikament for behandling av sovnforstyrrelser - Google Patents
Anvendelse av mirtazapin for fremstilling av medikament for behandling av sovnforstyrrelser Download PDFInfo
- Publication number
- NO328007B1 NO328007B1 NO20023803A NO20023803A NO328007B1 NO 328007 B1 NO328007 B1 NO 328007B1 NO 20023803 A NO20023803 A NO 20023803A NO 20023803 A NO20023803 A NO 20023803A NO 328007 B1 NO328007 B1 NO 328007B1
- Authority
- NO
- Norway
- Prior art keywords
- mirtazapine
- sleep
- treatment
- day
- drug
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims description 39
- 229960001785 mirtazapine Drugs 0.000 title claims description 39
- 208000019116 sleep disease Diseases 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title description 13
- 208000020685 sleep-wake disease Diseases 0.000 claims description 4
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical group C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 1
- 230000007958 sleep Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200499 | 2000-02-11 | ||
| PCT/EP2001/001221 WO2001058453A1 (fr) | 2000-02-11 | 2001-02-06 | Utilisation de mirtazapine pour traiter des troubles du sommeil |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023803D0 NO20023803D0 (no) | 2002-08-09 |
| NO20023803L NO20023803L (no) | 2002-10-09 |
| NO328007B1 true NO328007B1 (no) | 2009-11-09 |
Family
ID=8171013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023803A NO328007B1 (no) | 2000-02-11 | 2002-08-09 | Anvendelse av mirtazapin for fremstilling av medikament for behandling av sovnforstyrrelser |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6933293B2 (fr) |
| EP (4) | EP1656937A1 (fr) |
| JP (1) | JP5039994B2 (fr) |
| KR (1) | KR20020069371A (fr) |
| CN (2) | CN1395487A (fr) |
| AR (1) | AR027394A1 (fr) |
| AT (1) | ATE317261T1 (fr) |
| AU (1) | AU780439B2 (fr) |
| BR (1) | BR0108261A (fr) |
| CA (1) | CA2396209C (fr) |
| CO (1) | CO5271706A1 (fr) |
| CZ (1) | CZ302368B6 (fr) |
| DE (1) | DE60117122T2 (fr) |
| DK (1) | DK1257278T3 (fr) |
| ES (1) | ES2258071T3 (fr) |
| HK (1) | HK1049122B (fr) |
| HU (1) | HUP0204391A3 (fr) |
| IL (2) | IL150290A0 (fr) |
| NO (1) | NO328007B1 (fr) |
| PE (1) | PE20011080A1 (fr) |
| PL (1) | PL206073B1 (fr) |
| RU (1) | RU2270680C2 (fr) |
| SK (1) | SK287396B6 (fr) |
| WO (1) | WO2001058453A1 (fr) |
| ZA (1) | ZA200205238B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040152055A1 (en) * | 2003-01-30 | 2004-08-05 | Gliessner Michael J.G. | Video based language learning system |
| UA83666C2 (ru) | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| EP1689371A2 (fr) * | 2003-11-25 | 2006-08-16 | Aurobindo Pharma Limited | Compositions pharmaceutiques de mirtazapine |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| CN101039664A (zh) * | 2004-10-14 | 2007-09-19 | 大金工业株式会社 | 气氛改变方法、用于该气氛改变方法的喷雾剂与喷雾装置 |
| JP2006137748A (ja) * | 2004-10-14 | 2006-06-01 | Daikin Ind Ltd | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 |
| JP2007284363A (ja) * | 2006-04-13 | 2007-11-01 | Daikin Ind Ltd | 噴霧剤 |
| MX2009010967A (es) | 2007-04-11 | 2009-12-15 | Organon Nv | Un metodo para la preparacion de mirtazapina. |
| JP6876003B2 (ja) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置 |
| CN111053735A (zh) * | 2020-02-25 | 2020-04-24 | 上海阶平医院管理有限公司 | 一种治疗失眠的冷敷凝胶 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| EP0813873B1 (fr) * | 1996-06-19 | 2002-02-13 | Akzo Nobel N.V. | Compositions pharmaceutiques comprenants de la mirtazapine et un ou plusieurs inhibiteurs sélectifs d'assimilation de sérotonine |
| ATE289816T1 (de) * | 1997-11-14 | 2005-03-15 | Akzo Nobel Nv | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen |
-
2001
- 2001-02-06 DK DK01902410T patent/DK1257278T3/da active
- 2001-02-06 SK SK1144-2002A patent/SK287396B6/sk not_active IP Right Cessation
- 2001-02-06 CN CN01803934A patent/CN1395487A/zh active Pending
- 2001-02-06 CA CA002396209A patent/CA2396209C/fr not_active Expired - Lifetime
- 2001-02-06 DE DE60117122T patent/DE60117122T2/de not_active Expired - Lifetime
- 2001-02-06 US US10/203,232 patent/US6933293B2/en not_active Expired - Lifetime
- 2001-02-06 WO PCT/EP2001/001221 patent/WO2001058453A1/fr active IP Right Grant
- 2001-02-06 JP JP2001557563A patent/JP5039994B2/ja not_active Expired - Lifetime
- 2001-02-06 IL IL15029001A patent/IL150290A0/xx unknown
- 2001-02-06 RU RU2002124141/15A patent/RU2270680C2/ru not_active IP Right Cessation
- 2001-02-06 BR BR0108261-2A patent/BR0108261A/pt not_active Application Discontinuation
- 2001-02-06 EP EP05109547A patent/EP1656937A1/fr not_active Ceased
- 2001-02-06 EP EP10178745A patent/EP2283840A1/fr not_active Withdrawn
- 2001-02-06 CN CNA2008100056868A patent/CN101229170A/zh active Pending
- 2001-02-06 EP EP01902410A patent/EP1257278B1/fr not_active Expired - Lifetime
- 2001-02-06 CZ CZ20022330A patent/CZ302368B6/cs not_active IP Right Cessation
- 2001-02-06 AT AT01902410T patent/ATE317261T1/de active
- 2001-02-06 KR KR1020027009536A patent/KR20020069371A/ko not_active Application Discontinuation
- 2001-02-06 PL PL356721A patent/PL206073B1/pl not_active IP Right Cessation
- 2001-02-06 ES ES01902410T patent/ES2258071T3/es not_active Expired - Lifetime
- 2001-02-06 EP EP05109549A patent/EP1658850A1/fr not_active Withdrawn
- 2001-02-06 HU HU0204391A patent/HUP0204391A3/hu unknown
- 2001-02-06 AU AU30247/01A patent/AU780439B2/en not_active Expired
- 2001-02-08 PE PE2001000141A patent/PE20011080A1/es not_active Application Discontinuation
- 2001-02-09 AR ARP010100585A patent/AR027394A1/es unknown
- 2001-02-09 CO CO01009904A patent/CO5271706A1/es not_active Application Discontinuation
-
2002
- 2002-06-18 IL IL150290A patent/IL150290A/en not_active IP Right Cessation
- 2002-06-28 ZA ZA200205238A patent/ZA200205238B/en unknown
- 2002-08-09 NO NO20023803A patent/NO328007B1/no not_active IP Right Cessation
-
2003
- 2003-02-24 HK HK03101379.6A patent/HK1049122B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gouzoulis-Mayfrank et al. | Psychopathological, neuroendocrine and autonomic effects of 3, 4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study: Results of an experimental double-blind placebo-controlled study | |
| Hindmarch et al. | Psychopharmacological effects of sertraline in normal, healthy volunteers | |
| EP1750766A2 (fr) | Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme | |
| NO328007B1 (no) | Anvendelse av mirtazapin for fremstilling av medikament for behandling av sovnforstyrrelser | |
| Schück et al. | Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers | |
| Green et al. | Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam | |
| Nicholson et al. | The H1-antagonist mequitazine: studies on performance and visual function | |
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| Newhouse et al. | Stimulant drug effects on performance and behavior after prolonged sleep deprivation: a comparison of amphetamine, nicotine, and deprenyl | |
| Deijen et al. | Effects of paroxetine and maprotiline on mood, perceptual-motor skills and eye movements in healthy volunteers | |
| Nicholson et al. | Modulation of catecholamine transmission and sleep in man | |
| EP4021433B1 (fr) | Traitement de symptômes induits par le cycle menstruel | |
| US20040241255A1 (en) | Pharmaceutical composition containing valerina officinalis extract | |
| TWI297607B (en) | The use of mirtazapine for the treatment of sleep disorders and pharmaceutical composition comprising mirtazapine | |
| Whalley et al. | Treatment of the classical manifestations of dementia and confusion | |
| MXPA02006710A (en) | The use of mirtazapine for the treatment of sleep disorders | |
| Tyuneva et al. | Specific features of depressive disorders in victims of sexual violence | |
| Qidwai | Drug Review | |
| WO2011051423A1 (fr) | Traitement ou prophylaxie de la démence, des troubles neurodégénératifs, de la schizophrénie, de l'adhd de la somnolence ou de l'épilepsie | |
| Yoshimura et al. | Low-dose oral risperidone lengthened sleep duration in healthy participants | |
| Powles | Four perspectives on depression and the depressive illnesses. | |
| US20130267533A1 (en) | 5ht1a agonists for treatment of high cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |